Neuroendocrine Tumor

Correlatives:

- IRB# 22591
  Preoperative PRRT versus surgical cytoreduction alone in metastatic pancreatic neuroendocrine tumors to the liver: a Phase II multi-institutional trial

Treatment of Advanced Neuroendocrine Tumors

- IRB# 23825
  Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

- IRB# 23106
  A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Treatment of Carcinoid Syndrome

- IRB# 19669
  Study 19669 Telotristat Ethyl Grade 1/Grade 2 confirmed Small Bowel NET

CROSS-DISEASE TRIALS:

- IRB# TBD
  EAY131 (MATCH)

KEY

<table>
<thead>
<tr>
<th>Status</th>
<th>Color</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open to Enrollment</td>
<td>Green</td>
</tr>
<tr>
<td>In Development</td>
<td>Yellow</td>
</tr>
<tr>
<td>Enrollment on Hold</td>
<td>Brown</td>
</tr>
</tbody>
</table>